肠道活菌制剂在慢性阻塞性肺疾病急性加重期患者合并呼吸衰竭治疗中的应用效果

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨肠道活菌制剂在合并呼吸衰竭的慢性阻塞性肺疾病急性加重（AECOPD）患者中的治疗价值。方法选取2019年5～10月昆明市第一人民医院甘美医院的60例合并呼吸衰竭的AECOPD患者为研究对象，按照随机数字表法分为对照组和治疗组，每组各30例。对照组给予常规治疗，治疗组给予常规治疗+肠道活菌制剂治疗。治疗2周后，比较两组治疗前后的炎症指标、营养状况。结果两组治疗前的白细胞（WBC）、中性粒细胞比例（N%）、C反应蛋白（CRP）比较，差异无统计学意义（P＞0.05）；治疗组治疗后的WBC 低于对照组，差异有统计学意义（P<0.05），而两组治疗后的N%、CRP 比较，差异无统计学意义（P＞0.05）；两组治疗后的WBC、N%、CRP 低于治疗前，差异均有统计学意义（P<0.05）。两组治疗前的血清清蛋白（ALB）、前清蛋白（PA）比较，差异无统计学意义（P＞0.05）；两组治疗后的ALB、PA比较，差异无统计学意义（P＞0.05）；治疗组治疗后的ALB、PA 高于治疗前，对照组治疗后的ALB 低于治疗前，差异均有统计学意义（P<0.05），而治疗后与治疗前的PA比较，差异无统计学意义（P＞0.05）。结论在合并有呼吸衰竭的AECOPD患者中使用肠道活菌制剂可降低患者炎症水平、改善营养状态，而改善其预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杜俊毅
	杨超
	邵静
	李航
	杨丽娟
	张华庆
	陈敏

关键词 ：肠道活菌制剂, 呼吸衰竭, 慢性阻塞性肺疾病急性加重, 治疗

Abstract：Objective To investigate the therapeutic value of intestinal probiotics in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with respiratory failure.Methods From May to October 201960 AECOPD patients with respiratory failure in Canmei Hospital of Kunming First People′s Hospital were selected.According to random number table methodthey were divided into control group and treatment group30 cases in each group.The control group was treated with routine treatmentand the treatment group was treated with routine treatment and intestinal live bacteria preparation.After 2 weeks of treatmentthe differences in inflammatory index and nutritional status before and after treatment were compared between the two groups.Results There were no significant differences in white blood cells (WBC)neutrophil ratio (N%) and C-reactive protein (CRP) between the treatment group and the control group before treatment (P＞0.05).The WBC after treatment in the treatment group was lower than that in the control group (P<0.05)but there were no significant differences in N%CRP between the two groups after treatment (P＞0.05).The WBCN%CRP after treatment of the two groups were lower than before treatmentand the differences were statistically significant (P<0.05).There were no significant differences in serum albumin (ALB) and prealbumin (PA) between two groups before treatment (P＞0.05).The serum ALB and PA after treatment in the treatment group were higher than those before treatment (P<0.05),the ALB after treatment in the control group was lower than that before treatmentand the differences were statistically significant (P<0.05)while the difference in the PA between after treatment and before treatment was not statistically significant (P＞0.05).Conclusion The use of intestinal live bacterial preparations in patients with AECOPD with respiratory failure can reduce inflammation and improve nutritional statusthereby improving prognosis.

Key words： Intestinal probiotics Respiratory failure Acute exacerbation of chronic obstructive pulmonary disease Treatment

基金资助:云南省昆明市西山区科技计划项目（西科字22号）

通讯作者: 陈敏（1983-），女，副主任医师，主要从事呼吸系统疾病研究

作者简介: 杜俊毅（1979-），男，副主任医师，主要从事呼吸系统疾病研究；杨超（1985-），男，主治医师，主要从事呼吸系统疾病研究

引用本文:

杜俊毅;杨超;邵静;李航;杨丽娟;张华庆;陈敏. 肠道活菌制剂在慢性阻塞性肺疾病急性加重期患者合并呼吸衰竭治疗中的应用效果[J]. 中国当代医药, 2020, 27(30): 43-46.
DU Jun-yi;YANG Chao; SHAO Jing; LI Hang; YANG Li-juan; ZHANG Hua-qing; CHEN Min. Application effect of intestinal probiotics in the treatment of acute exacerbation of chronic obstructive pulmonary disease patients with respiratory failure. 中国当代医药, 2020, 27(30): 43-46.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I30/43

[1]	Wang C，Xu J，Yang L，et al.Prevalence and risk factors of chronic obstructive pulmonary disease in China （the China Pulmonary Health [CPH]study）：A national cross-sectional study[J].Lancet，2018，391（10 131）：1706-1717.
[2]	Sharifi H，Masjedi MR，Emami H，et al.Interim report from burden of obstructive lung disease （BOLD Study）in Tehran：prevalence and risk factors of chronic obstructive pulmonary disease[J].Tanaffos，2014，13（3）：6-13.
[3]	Schuijt TJ，Lankelma JM，Scicluna BP，et al.The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia[J].Gut，2016，65（4）：575-583.
[4]	刘鸿翔，南勇，石斌.慢性阻塞性肺疾病急性加重期合并呼吸衰竭患者的痰病原菌学分析[J].实用医学杂志，2013，29（8）:1347-1349.
[5]	Nakamura Y，Harada K，Yamamoto I，et al.Human pulmonary hypoplasia.Statistical，morphological，morphometric，and biochemical study[J].Arch Pathol Lab Med，1992，116（6）：635-642.
[6]	Chung KF.Airway microbial dysbiosis in asthmatic patients：A target for prevention and treatment?[J].J Allergy Clin Immunol，2017，139（4）：1071-1081.
[9]	王凤科.广谱抗生素对感染性疾病患者肠道微生态的影响[J].吉林医学，2010，31（32）：5726-5728.
[11]	Nussbaumer-Ochsner Y，Rabe KF.Systemic manifestations of COPD[J].Chest，2011，139（1）：165-173.
[14]	Couillard A，Muir JF，Veale D.COPD recent findings：impact on clinical practice[J].COPD，2010，7（3）：204-213.
[7]	He Y，Wen Q，Yao F，et al.Gut-lung axis：The microbial contributions and clinical implications[J].Crit Rev Microbiol，2017，43（1）：81-95.
[8]	Marshall JC，Christou NV，Meakins JL.The gastrointestinal tract the "undrained abscess" of multiple organ failure[J].Ann Surg，1993，218（2）：111-119.
[10]	Sarah K，Julie G，Mary ES，et al.Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions：a systematic review and meta-analysis[J].Br J Nutr，2014，112（1）：41-54.
[12]	Odencrants S，Ehnfors M，Ehrenberg A.Nutritional status and patient characteristics for hospitalized older patients with chronic obstructive pulmonary disease[J].J Clin Nurs，2008，17（13）：1771-1778.
[13]	Gupta B，Kant S，Mishra R，et al.Nutritional status of chronic obstructive pulmonary disease patients admitted in hospital with acute exacerbation[J].J Clin Med Res，2010，2（2）：68-74.
[15]	Lee H，Kim S，Lim Y，et al.Nutritional status and disease severity in patients with chronic obstructive pulmonary disease（COPD）[J].Arch Gerontol Geriatr，2013，56（3）：518-523.